DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

and focuses on innovation in sensor accuracy, wearable technology, and integration with insulin pumps and digital health platforms. DexCom, Inc. (NASDAQ:DXCM) delivered strong performance in 2024 ...

With the salesforce ramping up and regulatory approval of the 15-day G7 sensor expected this year, we anticipate Dexcom can return to double-digit top and bottom-line growth in 2025. We think the ...

Stelo CGM Launch: In August 2024, DexCom announced the commercial launch of Stelo CGM, the first over-the-counter glucose sensor in the U.S. for non-insulin using Type 2 diabetes and prediabetes ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring blood glucose levels ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Any time we try a healthy new way of eating, it’s easy for doubt to creep in. Is it really working? Is it worth it? Does it ...

and focuses on innovation in sensor accuracy, wearable technology, and integration with insulin pumps and digital health platforms. DexCom, Inc. (NASDAQ:DXCM) delivered strong performance in 2024 ...